Meeting Coverage


Multidisciplinary Head and Neck Cancer Symposium

Novel Therapies Active in Head and Neck Cancers

High response rate with oncolytic virus plus immunotherapy in cutaneous lesions

A close up of cutaneous squamous cell carcinoma on a senior man’s cheek.

Latest MHNCS Meeting Coverage

OncoBriefs: Zalutumumab Misses Mark in H&N Cancer

SCOTTSDALE, Ariz. -- Chemoradiation plus the targeted agent zalutumumab failed to improve disease control or survival in patients with squamous cell head and neck cancer, a finding that leads this roundup of news from the Multidisciplinary Head and Neck Cancer Symposium.

February 22, 2014
Oral Shield Cuts Radiation to Normal Tissue

PHOENIX -- Patients with head and neck cancer had substantial sparing of oral mucosa when they used custom-made dental stents to shield normal tissue from radiation therapy, data from a small clinical series showed.

January 31, 2012
Jaw Necrosis Common after Radiation for Oral Cancer

PHOENIX -- Osteoradionecrosis of the jaw occurred more than twice as often in patients treated for oral cancer as reported in the literature, according to a population-based study.

January 30, 2012